SCHEMBL4170629

SCHEMBL4170629

COc1cc(Nc2nccc(-c3sc(-c4cccnc4)nc3C)n2)ccc1N1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.53
ACVR1 Q04771 2/20 0.53
CDK2 P24941 10/20 0.53
AURKA O14965 6/20 0.53
CDK4 P11802 6/20 0.53
AURKB Q96GD4 6/20 0.53
CDK9 P50750 9/20 0.53
CDK1 P06493 6/20 0.53
CCNT1 O60563 5/20 0.51
JAK2 O60674 3/20 0.51
TNIK Q9UKE5 3/20 0.51
PRKD3 O94806 2/20 0.51
LCK P06239 2/20 0.51
JAK3 P52333 2/20 0.51
CDC7 O00311 1/20 0.51
PLK4 O00444 1/20 0.51
CIT O14578 1/20 0.51
CHEK1 O14757 1/20 0.51
GAK O14976 1/20 0.51
EPHB6 O15197 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4173630 0.90 CDK2 (0.55) ACVR1CDK2AURKACDK4AURKB
SCHEMBL4159168 0.86 CDK2 (0.71) IGF1RACVR1CDK2AURKACDK4
SCHEMBL4173509 0.86 CDK2 (0.71) IGF1RACVR1CDK2AURKACDK4
SCHEMBL4159803 0.84 CDK2 (0.72) IGF1RACVR1CDK2AURKACDK4
SCHEMBL4161793 0.83 CDK2 (0.74) IGF1RACVR1CDK2AURKACDK4
SCHEMBL4170636 0.82 PRKCA (0.54) CDK2AURKACDK4AURKBCDK9
SCHEMBL4160392 0.82 CDK2 (0.59) IGF1RACVR1CDK2AURKACDK4
SCHEMBL4171347 0.82 CDK2 (0.56) IGF1RACVR1CDK2AURKACDK4
SCHEMBL4164547 0.82 ACVR1 (0.53) IGF1RACVR1CDK2AURKACDK4
SCHEMBL4159124 0.81 ZAP70 (0.72) CDK2AURKACDK4AURKBCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US claimed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP claimed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO claimed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 IGF1R 3125/4885ACVR1 3255/4885CDK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.